JP2013518049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518049A5 JP2013518049A5 JP2012550135A JP2012550135A JP2013518049A5 JP 2013518049 A5 JP2013518049 A5 JP 2013518049A5 JP 2012550135 A JP2012550135 A JP 2012550135A JP 2012550135 A JP2012550135 A JP 2012550135A JP 2013518049 A5 JP2013518049 A5 JP 2013518049A5
- Authority
- JP
- Japan
- Prior art keywords
- lactide
- intraluminal implant
- therapeutic agent
- implant according
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007943 implant Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 3
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical group CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 3
- 229960002470 bimatoprost Drugs 0.000 claims 3
- 238000002513 implantation Methods 0.000 claims 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 210000002159 anterior chamber Anatomy 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29766010P | 2010-01-22 | 2010-01-22 | |
| US61/297,660 | 2010-01-22 | ||
| PCT/US2011/021971 WO2011091205A2 (en) | 2010-01-22 | 2011-01-21 | Intracameral sustained release therapeutic agent implants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518049A JP2013518049A (ja) | 2013-05-20 |
| JP2013518049A5 true JP2013518049A5 (https=) | 2014-03-06 |
| JP5809169B2 JP5809169B2 (ja) | 2015-11-10 |
Family
ID=43795202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550135A Active JP5809169B2 (ja) | 2010-01-22 | 2011-01-21 | 治療薬持続放出型腔内インプラント |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US8647659B2 (https=) |
| EP (3) | EP3085358B1 (https=) |
| JP (1) | JP5809169B2 (https=) |
| KR (4) | KR20180117211A (https=) |
| CN (2) | CN102821753A (https=) |
| AU (1) | AU2011207281B2 (https=) |
| BR (1) | BR112012018134B1 (https=) |
| CA (1) | CA2787514C (https=) |
| DK (2) | DK3085358T3 (https=) |
| ES (2) | ES2561083T3 (https=) |
| RU (1) | RU2565445C2 (https=) |
| WO (1) | WO2011091205A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8968396B2 (en) | 2007-07-23 | 2015-03-03 | Powervision, Inc. | Intraocular lens delivery systems and methods of use |
| US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| EP2432420A4 (en) | 2009-05-18 | 2018-01-10 | Dose Medical Corporation | Drug eluting ocular implant |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| JP5635605B2 (ja) | 2009-07-09 | 2014-12-03 | イバンティス インコーポレイテッド | 眼内インプラント及び眼内インプラントを眼球内に送出するための方法 |
| US9693899B2 (en) | 2009-07-09 | 2017-07-04 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
| CN102821753A (zh) * | 2010-01-22 | 2012-12-12 | 阿勒根公司 | 前房内持续释放治疗药植入物 |
| EP3263574B1 (en) | 2010-02-23 | 2019-04-03 | PowerVision, Inc. | Accomodating intraocular lens |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US20120276186A1 (en) | 2011-04-29 | 2012-11-01 | Ghebremeskel Alazar N | Sustained release latanoprost implant |
| US10245178B1 (en) * | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
| US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
| US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
| WO2014066653A1 (en) * | 2012-10-26 | 2014-05-01 | Allergan, Inc. | Ketorolac-containing sustained release intraocular drug delivery systems |
| US20150272877A1 (en) * | 2012-10-26 | 2015-10-01 | Allergan, Inc. | Ketorolac-containing sustained release drug delivery systems |
| WO2014085450A1 (en) | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
| WO2014159576A1 (en) * | 2013-03-14 | 2014-10-02 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| EP2967842B1 (en) | 2013-03-15 | 2020-11-04 | Alcon Inc. | Method of reconfiguring an intraocular lens for delivery to a delivery device |
| WO2014143754A2 (en) * | 2013-03-15 | 2014-09-18 | Allergan, Inc. | Prostamide-containing intraocular implant |
| AU2014248460B2 (en) | 2013-04-01 | 2019-04-11 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| PT3062775T (pt) | 2013-10-31 | 2018-03-06 | Allergan Inc | Implantes intraoculares contendo prostamida e métodos para a sua utilização |
| US20160296627A1 (en) * | 2013-12-06 | 2016-10-13 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
| AU2015266850B2 (en) | 2014-05-29 | 2019-12-05 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2016011056A1 (en) | 2014-07-14 | 2016-01-21 | Ivantis, Inc. | Ocular implant delivery system and method |
| US9931306B2 (en) | 2014-09-06 | 2018-04-03 | Integral Biosystems Llc | Methods and biocompatible compositions to achieve sustained drug release in the eye |
| EP3302382A4 (en) * | 2015-05-29 | 2019-02-20 | Allergan, Inc. | IMPLANT FOR THE TREATMENT OF OCULAR DISEASE |
| KR20260025887A (ko) * | 2015-06-06 | 2026-02-24 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
| JP6839100B2 (ja) | 2015-06-10 | 2021-03-03 | アルコン インコーポレイティド | 眼内レンズ材料及び部材 |
| EP4265231A3 (en) | 2015-08-14 | 2023-12-20 | Alcon Inc. | Ocular implant with pressure sensor |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
| PT109154B (pt) * | 2016-02-12 | 2019-11-05 | Univ De Coimbra | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos |
| AU2017252294B2 (en) | 2016-04-20 | 2021-12-02 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| AU2017274195B2 (en) | 2016-06-02 | 2022-04-07 | Ads Therapeutics Llc | Compositions and methods of using nintedanib for improving glaucoma surgery success |
| EP3515406B1 (en) | 2016-09-23 | 2024-07-24 | Incept, LLC | Intracameral drug delivery depots |
| EP4046609B1 (en) * | 2016-09-30 | 2025-02-26 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
| WO2018169967A1 (en) | 2017-03-14 | 2018-09-20 | Allergan, Inc. | Acorafloxacin in treating ocular infections |
| US10765629B2 (en) | 2017-07-25 | 2020-09-08 | Allergan, Inc. | Solid complex, preparations and uses thereof |
| US20190192341A1 (en) * | 2017-11-09 | 2019-06-27 | Allergan, Inc. | Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect |
| EP3755287B1 (en) | 2018-02-22 | 2024-04-03 | Alcon Inc. | Ocular implant |
| CN112566622A (zh) * | 2018-06-19 | 2021-03-26 | 细胞疗法有限责任公司 | 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统 |
| TW202021584A (zh) | 2018-08-21 | 2020-06-16 | 美商歐樂根公司 | α2 腎上腺素受體促效劑用於改善視力之用途 |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| WO2020047144A2 (en) * | 2018-08-30 | 2020-03-05 | Liu Yunxiang | Ophthalmic formulations, process for preparing the same and method for administering the same |
| PT3861985T (pt) | 2020-02-06 | 2023-08-03 | Ocular Therapeutix Inc | Composições e métodos para tratar doenças oculares |
| CA3168748A1 (en) | 2020-02-20 | 2021-08-26 | Mohammed DIBAS | Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes |
| CN115443125A (zh) | 2020-02-20 | 2022-12-06 | 阿勒根公司 | α-2-肾上腺素能受体激动剂的药物组合物和其用于改善视力的用途 |
| EP4142664A4 (en) | 2020-04-27 | 2024-05-29 | Ocular Therapeutix, Inc. | METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS |
| CA3202776A1 (en) | 2021-01-11 | 2022-07-14 | Wayne A. Noda | Systems and methods for viscoelastic delivery |
| WO2022251710A2 (en) | 2021-05-28 | 2022-12-01 | Sight Sciences, Inc. | Intraocular devices, systems, and methods |
| CN115607741B (zh) * | 2022-09-08 | 2023-11-24 | 西安德诺海思医疗科技有限公司 | 一种青光眼外科手术用复合生物材料及其应用 |
| WO2025255203A1 (en) * | 2024-06-06 | 2025-12-11 | Ocular Therapeutix, Inc. | Compositions and methods for treating ocular diseases |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3749776A (en) * | 1970-08-28 | 1973-07-31 | Allergan Pharma | Method for blocking prostaglandin activity |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| US5612027A (en) * | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US5994309A (en) | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| IL151530A0 (en) | 2000-07-14 | 2003-04-10 | Allergan Sales Inc | Compositions containing alpha-2-adrenergic agonist components |
| WO2002058730A2 (en) | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| EP1339438B1 (en) | 2000-11-29 | 2005-10-19 | Allergan Inc. | Preventing transplant rejection in the eye |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7799326B2 (en) * | 2001-09-24 | 2010-09-21 | Mount Sinai School Of Medicine | Methods and compositions for cathespin k complex-mediated disorders |
| RU2355385C2 (ru) * | 2002-11-06 | 2009-05-20 | Алза Корпорейшн | Композиции пролонгированного действия с контролируемым высвобождением |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20120283232A9 (en) * | 2003-11-12 | 2012-11-08 | Zhengjun Wang | Process for making a pharmaceutical composition |
| US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| DE602005011928D1 (de) * | 2004-01-20 | 2009-02-05 | Allergan Inc | Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US7993634B2 (en) * | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8722097B2 (en) * | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US7589057B2 (en) * | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| US20070293873A1 (en) * | 2006-06-19 | 2007-12-20 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
| US9039761B2 (en) * | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) * | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US8231892B2 (en) * | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US20110152328A1 (en) | 2008-04-16 | 2011-06-23 | Whitcup Scott M | Combination Therapy For Glaucoma |
| EP2296621A1 (en) | 2008-05-20 | 2011-03-23 | Yale University | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
| US20100104654A1 (en) * | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US8545554B2 (en) * | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| CN102821753A (zh) * | 2010-01-22 | 2012-12-12 | 阿勒根公司 | 前房内持续释放治疗药植入物 |
| WO2011109384A2 (en) | 2010-03-02 | 2011-09-09 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| US9095591B2 (en) * | 2010-06-28 | 2015-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Pharmaceutical composition for use in the treatment of glaucoma |
| US20120276186A1 (en) * | 2011-04-29 | 2012-11-01 | Ghebremeskel Alazar N | Sustained release latanoprost implant |
-
2011
- 2011-01-21 CN CN2011800149985A patent/CN102821753A/zh active Pending
- 2011-01-21 KR KR1020187030084A patent/KR20180117211A/ko not_active Ceased
- 2011-01-21 US US13/011,467 patent/US8647659B2/en not_active Expired - Fee Related
- 2011-01-21 DK DK15191632.7T patent/DK3085358T3/en active
- 2011-01-21 KR KR1020207007048A patent/KR102126007B1/ko not_active Expired - Fee Related
- 2011-01-21 EP EP15191632.7A patent/EP3085358B1/en active Active
- 2011-01-21 KR KR1020127021839A patent/KR101911960B1/ko not_active Expired - Fee Related
- 2011-01-21 KR KR1020207017535A patent/KR102337046B1/ko not_active Expired - Fee Related
- 2011-01-21 ES ES11701723.6T patent/ES2561083T3/es active Active
- 2011-01-21 EP EP17001789.1A patent/EP3320892A1/en not_active Withdrawn
- 2011-01-21 EP EP11701723.6A patent/EP2525776B1/en active Active
- 2011-01-21 JP JP2012550135A patent/JP5809169B2/ja active Active
- 2011-01-21 CN CN201710411369.5A patent/CN107184544A/zh active Pending
- 2011-01-21 ES ES15191632.7T patent/ES2658175T3/es active Active
- 2011-01-21 WO PCT/US2011/021971 patent/WO2011091205A2/en not_active Ceased
- 2011-01-21 DK DK11701723.6T patent/DK2525776T3/en active
- 2011-01-21 BR BR112012018134-3A patent/BR112012018134B1/pt active IP Right Grant
- 2011-01-21 CA CA2787514A patent/CA2787514C/en active Active
- 2011-01-21 RU RU2012133880/15A patent/RU2565445C2/ru active
- 2011-01-21 AU AU2011207281A patent/AU2011207281B2/en active Active
-
2013
- 2013-09-19 US US14/031,657 patent/US9061065B2/en active Active
-
2015
- 2015-06-22 US US14/746,438 patent/US9504696B2/en active Active
-
2016
- 2016-11-28 US US15/362,197 patent/US10278919B2/en active Active
-
2019
- 2019-05-06 US US16/403,965 patent/US20190254965A1/en not_active Abandoned
- 2019-12-18 US US16/718,640 patent/US20200121593A1/en not_active Abandoned
-
2020
- 2020-10-23 US US17/079,148 patent/US20210169780A1/en not_active Abandoned
-
2023
- 2023-08-21 US US18/236,215 patent/US20240148643A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518049A5 (https=) | ||
| RU2012133880A (ru) | Внутрикамерные имплантаты с пролонгированным высвобождением терапевтического агента | |
| US9943404B2 (en) | Intraocular cell migration inhibition system | |
| JP2021502366A5 (https=) | ||
| US10548766B2 (en) | Biocompatible biodegradable intraocular implant system | |
| US8551167B2 (en) | Intraocular implant cell migration inhibition system | |
| SI3062775T1 (en) | Intraocular implants containing prostamide and methods for their use | |
| US10736735B2 (en) | Devices and methods for stabilization of an ocular lens capsule and preventing artificial intraocular lens implant rotation post cataract surgery | |
| Gonnermann et al. | Posterior iris-claw aphakic intraocular lens implantation in children | |
| Argento et al. | Optic capture of the AcrySof intraocular lens in pediatric cataract surgery | |
| JP2014518644A (ja) | 形状記憶ポリマー眼内レンズ | |
| McNab | Hydroxyapatite orbital implants Experience with 100 cases | |
| JP2013520239A (ja) | 網膜を再構成するための最小限侵襲方法及び装置 | |
| CN106456584A (zh) | 用于矫正老视的药理学眼科用组合物和其施用 | |
| García-Feijoo et al. | Angle-closure glaucoma after piggyback intraocular lens implantation | |
| CN212662027U (zh) | 一种人工晶状体的环形囊袋 | |
| Rosen et al. | Endocapsular cataract extraction | |
| Rosenthal et al. | The Artisan Iris Claw Lens for Anterior Iris Fixation | |
| Agarwal et al. | Reply: Fibrin glue–assisted sutureless scleral fixation | |
| Lee et al. | Long-term results of Descemet's stripping automated endothelial keratoplasty in Korea | |
| Shrestha | Cataract surgery in children: Controversies and practices | |
| Bylsma | Correction of Keratometric Astigmatism: Staar Toric IOL Refractive Lens Surgery | |
| Güell et al. | Phakic Intraocular Lenses | |
| Foam-Covered | Case 160: Double Folds | |
| Falavarjani et al. | Fibrin glue–assisted sutureless scleral fixation |